首页> 外文期刊>Acta medica Iranica. >Prognostic Value of KI6 Biomarker in Predict Short Time Prognosis of Low Grade Cervical Intraepithelial Neoplasia in HPV Negative and Positive Patients
【24h】

Prognostic Value of KI6 Biomarker in Predict Short Time Prognosis of Low Grade Cervical Intraepithelial Neoplasia in HPV Negative and Positive Patients

机译:KI6生物标志物在预测阴性和阳性HPV患者低度宫颈上皮内瘤变的短期预后中的预后价值

获取原文
           

摘要

Screening of cervical cancer is the most common gynecologic cancer in developing countries. Despite being preventable, but we have still some problems with the screening of this cancer. Recently, many studies have been done on immunohistochemistry to improve screening of cervical intraepithelial neoplasia (CIN) as a precancerous lesion. But, the majority of the studies are based on cytological samples. The objective of this study was to analyze the correlation KI-67 biomarker and HPV infection in predict short time prognosis in CIN as an alternative or auxiliary method to the current screening method in a different geographic population. This descriptive cohort prospective study included 40 patients with a diagnosis of CIN based on cervical punch biopsy samples after colposcopy examination. They were referred to the department of gynecology and oncology of an academic hospital, Mashhad University of 2016 to 2017. All samples were investigated for HR- HPV DNA with Cobas test and immunostaining for KI-67 biomarker. Finally, after one year follows up, the prognosis for all patients was evaluated. Data were analyzed by SPSS software program version 23.0 and Mann-Whitney U test and Fisher's exact test. P 0.05 was considered significant. Significant difference was found between HR-HPV positive and negative tests in KI-67 expression ( P 0.001), but no significant difference was observed in reactivity level ( P =0.5), also no significant difference was found in KI-67 expression in the metaplastic and non-metaplastic epithelium ( P =0.88). KI-67 biomarker is recommended as complementary screening tests not alternative for differentiating in high risks patients with CIN1. The patients with low KI-67 / HR-HPV positive test could be offered for a less aggressive follow-up protocol.
机译:子宫颈癌的筛查是发展中国家最常见的妇科癌症。尽管可以预防,但是我们在筛查该癌症方面仍然存在一些问题。最近,已经进行了许多免疫组织化学研究,以改善对子宫颈上皮内瘤变(CIN)作为癌前病变的筛查。但是,大多数研究是基于细胞学样本的。这项研究的目的是分析KI-67生物标志物与HPV感染的相关性,以预测CIN的短期预后,作为在不同地理人群中当前筛查方法的替代或辅助方法。这项描述性队列前瞻性研究包括40例经阴道镜检查后根据宫颈穿孔活检样本诊断为CIN的患者。他们于2016年至2017年被转诊至马什哈德大学学术医院的妇科和肿瘤科。所有样品均采用Cobas检测法检测HR-HPV DNA,并针对KI-67生物标记物进行免疫染色。最后,经过一年的随访,评估了所有患者的预后。数据通过SPSS软件程序23.0版以及Mann-Whitney U检验和Fisher精确检验进行分析。 P <0.05被认为是显着的。 HR-HPV阳性和阴性试验在KI-67表达上有显着差异(P <0.001),但在反应性水平上未见显着差异(P = 0.5),在KI-67表达上也无显着差异。上皮化生和非上皮化(P = 0.88)。推荐使用KI-67生物标志物作为补充筛选测试,而不是区分CIN1高危患者的替代选择。 KI-67 / HR-HPV阳性检测结果低的患者可以接受较不积极的随访方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号